TPG Auriga Takes 12.6% Stake in Achieve Life Sciences, Appoints Board Member

summarizeSummary

TPG Auriga has acquired a 12.6% beneficial ownership stake in Achieve Life Sciences through a $25 million private placement, securing a board seat and providing crucial capital.

check_boxKey Events

• Strategic Investment by TPG Auriga

  TPG Auriga acquired 6,877,580 shares of common stock and 6,877,580 warrants for an aggregate purchase price of $25,000,003.30, closing on April 17, 2026. This follows the private placement announced on April 16, 2026.

• Significant Ownership Stake

  TPG Auriga now beneficially owns 13,755,160 shares, representing approximately 12.6% of the company's outstanding common stock (including exercisable warrants).

• Board Representation Secured

  Lucian Iancovici, a TPG designee, has been appointed to the Issuer's Board of Directors, effective April 17, 2026, and will be nominated for re-election at upcoming annual meetings.

• Critical Capital Infusion

  This private placement provides a crucial capital injection for Achieve Life Sciences, following recent disclosures of a 'going concern' warning and FDA regulatory issues.

auto_awesomeAnalysis

This Schedule 13D confirms a significant strategic investment by TPG Auriga, a major institutional investor, into Achieve Life Sciences. The $25 million private placement, which includes both common stock and warrants, represents a substantial capital injection for the company, especially in light of its recent 'going concern' warning and FDA regulatory challenges. The appointment of a TPG-designated director to the board signals active involvement and potential strategic guidance from a prominent financial firm, which could be a positive catalyst for the company's future direction and stability. This filing provides specific details following the general announcement of a private placement on April 16, 2026.